fda drug safety communication semaglutide naion 2025 clarifies policies for compounders as national GLP-1 supply begins to stabilize The FDA sent a warning

People who lost their eyesight or experienced NAION while taking Wegovy should talk to a lawyer about their legal options

Platforms like GLP-1 tracking apps centralize injection schedules, hydration, and protein targets, side-effect timelines, and trend visuals, turning fragmented notes into actionable patterns and reducing the time clinicians need to determine whether hunger shifts are medication- or lifestyle-driven

Having access to peptide testing laboratories that can verify potency can provide reassurance in these situations

Administration Routine: Wash your hands and clean the chosen skin spot with an alcohol swab